http://www.novartis.com/

Bill Sellers, MD - VP & Global Head, Oncology
Stephen Fawell, PhD - Executive Director Drug Discovery II

Presentation on:

• Nilotinib-BCR-Abl inhibitor
• RAD001-mTOR inhibitor
• BEZ235- PI3K inhibitor
• RAF265- RAF inhibitor
• TKI 258- Multiple Kinase inhibitor
• HCD122- Anti- CD4O Antibody
• Overview Preclinical Projects/ Apoptosis
  
  

---

http://www.nervianoms.com/cont/en/home-page.asp

Bernard. Laffranchi, MD – Director of Clinical Research
Silvia Comis, MD - Senior Director of Clinical Development
Juergen Moll, PhD – Director, Department of Cell Biology

Presentation on:

• PHA-739358  - Aurora Kinase Inhibitor
• PHA-767491 – CDK Inhibitor

---

http://www.infi.com

Julian Adams, PhD – President, Chief Scientific Officer
Jeffrey Tong, PhD - Vice President, Corporate Product Development 

Presentation on:

 IPI-609 – Hedgehog Signalling Inhibitor

---

http://pfizer.com/pfizer/main.jsp

Pierre Dodion, MD- Group Leader, US Medical Oncology, Pfizer Global Pharmaceuticals, NY
Louis J. Denis, MD - Clinical Research and Development, Oncology,
Pfizer Global Research and Development, New London, CT

Presentation on:

• CP675.206 - a monoclonal antibody against CTLA4
• PF3521,676 - a toll-like receptor agonist
• Axitinib (AG13736)
• Sutent – http://www.sutent.com

---

http://www.genzyme.com/

Johanne Kaplan, PhD - Vice President, Oncology Research
Jim Lillie, PhD - Vice President, Biochemistry
Frank Hsu, MD - Medical Director, Clinical Research

Presentation on:

• Oncology Research at Genzyme
• Small molecule discovery program at Genzyme
• Generation of therapeutic antibodies
• Campath research - http://www.campath.com/
• Clinical programs: Campath; Clofarabine; anti-TGFb monoclonal antibody (GC1008) 

---

http://www.emdserono.com/index.html

Paul Lammers, MSc - Chief Medical Officer, Serono, Inc. (Clinical and Current Pipeline)
Steve Arkinstall, D.Phil - Vice President, Research, Serono Research Institute, Inc. (Preclinical and Research Efforts)
Heather Hatfield - Director, Corporate and Scientific Communications
Ben Askew, PhD - Director of Chemistry
John Hermann, PhD - Director, Oncology Business Opportunities

Presentation on:

• AS-703569 – Aurora Kinase Inhibitor
• AS-602868 – IKK2 inhibitor

---

 

 http://www.gpc-biotech.com/en/index.html

Martine George, MD, MSc – SVP, Clinical Development
Hannes Loferer, PhD – Senior Director, Research Project Management
Maureen Caliguri, PhD – Principal ScientistLou Lamphere, PhD – Director Pharmacology
Nicolai Kley, PhD – Head of ResearchMarcel Rosencweig – CMO and SVP Drug Development

Presentation on:

• Satraplatin
• ID09C3 Monoclonal Antibody
• Cell-Cyle inhibitors

 

---

http://www.arraybiopharma.com/

Mark Miglarese, PhD – Assistant Director Translational Research
Mike Doyle, MD – Director, Clinical Development and Regulatory Affairs

Presentation on:

• ARRY-797 – p38 alpha inhibitor
• ARRY-886 – MEK inhibitor
• ARRY-520 – KSP inhibitor

 

---

http://www.bms.com/landing/data/index.html

Renzo Canetta, MD - VP Oncology Global Research - Oncology and Immunology Susan Galbraith, PhD -  ED, Clinical Discovery - Oncology and Immunology Steven Averbuch,  MD - ED, Oncology Global Clinical Research Roberto Weinman, PhD - Director Discovery Biology
Edwin Clark, PhD - Director Oncology Biomarker Team

Presentation on:

• Late Stage Development: Erbitux (http://www.erbitux.com) , Dasatinb , Ixabepilone and Vinflunine
• Immunology: Ipilimumab and CD-137, Angiogenesis, VEGFR/FGFR
• Early Development: Oral Taxane, Androgen Receptor Inhibitor, Multi-targeted Kinase Inhibitor
• Preclinical Themes
• Pharmacogenomics

---

http://www.mlnm.com/

Michael Cooper,  MD - Head, Oncology Clinical Research, Senior Medical Director, Oncology Clinical Research
Dixie-Lee Esseltine, MD - Senior Medical Director, Oncology Clinical Research

Presentation on:

•  MLN8045, an aurora kinase inhibitor
• Further clinical development of Velcade – http://www.mlnm.com/products/velcade/index.asp

---

http://www.astrazeneca.com

Louise Grochow, MD - Senior Director, Clinical Research
Cathleen Wheeler, MD - Emerging Product Team Director
Jeff Hanke, PhD - Vice President Cancer Research

Presentation on:

• AZD-6474 (Vandetanib, Zactima - VEGFR-2/KDR tyrosine kinase inhibitor )
• AZD-2171 (VEGFR Kinase inhibitor)
• AZD-1152 (Aurora Kinase Inhibitor)
• AZD-0530 (Abl Kinase-, Src Kinase Inhibitor)
• AZD-7762 (Check Point Inhibitor)
• AZD-6244 (MEK-1, MEK-2 Inbibitor)
• PARPi (Poly(ADP-ribose) Polymerase Inhibitors)

---

http://www.abraxisbio.com/

Michael J. Hawkins, MD - Chief Medical Officer
Neil Desai PhD - Vice President, R&D

Presentation on:

• Update on Abraxane Clinical Trials:
• Non-Small Cell Lung Cancer
• Malignant Melanoma
• Ph I- In Combination with Carboplatin
• Correlation of Response with SPARC Expression in Head & Neck
• http://www.abraxane.com/
• Preclinical Development Program
• Mechanistics and Applications of Nab-Technology
• Pipeline Products:
  • nab-17AAG
  • nab-rapamycin
  • nab-thiocolchicine dimer
  • nab-docetaxel